Drug recall
Drug recall
Find pharmacy-related safety alerts, drug recall and new generic drug announcements, and other medication information.
Pharmacy news bulletins available on the portal
For a list of pharmacy news bulletins, pharmacists may sign in to the
The Inflation Reduction Act (IRA) became law on August 16, 2022 and includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government
Notifications and prior authorizations
Drug recalls
Additional notifications
Information about generic Namzaric
Effective Jan. 18, 2025, generic Namzaric (memantine HCl and donepezil HCl) is not covered on Humana’s Medicare Advantage prescription drug plans. Brand-name Namzaric will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time.
An important update regarding prescription drug coverage for Lagevrio (molnupiravir)
Emergency Use Authorization (EUA)-labeled Lagevrio™ (molnupiravir) was removed from Humana’s formulary on Jan. 1, 2025, because it no longer meets the definition of a Medicare Part D drug, effective April 1, 2025.
Paxlovid™ (nirmatrelvir tablets, ritonavir tablets) will remain covered on Humana’s formulary as an oral antiviral for the treatment of COVID-19.
You can submit a request for Humana to make an exception by calling Humana Clinical Pharmacy Review at 800-555-CLIN (2546) (TTY: 711), Monday – Friday, 8 a.m. – 6 p.m., Eastern time. For prescription drug coverage requests in Puerto Rico, please call 866-773-5959 (TTY: 711), Monday – Friday, 8 a.m. – 8 p.m., Eastern time.
Information about generic Advair HFA
Effective Jan. 1, 2025, generic Advair HFA (fluticasone/salmeterol) is not covered on Humana’s Medicare Advantage prescription drug plans. Brand-name Advair HFA will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time.
Information about generic Combigan
Effective Jan. 1, 2025, generic Combigan (brimonidine-timolol) is not covered on Humana’s Medicare Advantage prescription drug plans. Brand-name Combigan will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (555-2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time.
Information about generic Symbicort HFA inhaler
Effective Jan. 1, 2025, generic Symbicort HFA inhaler (budesonide/formoterol inhaler) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Symbicort HFA inhaler will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (555-2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991, Monday – Friday, 8 a.m. – 8 p.m., Atlantic time.
An important update regarding prescription drug coverage for HIV PrEP
Currently, antiretroviral drugs used for the prevention of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) are covered under Medicare Part D. To assist you in the care of your patients, we are notifying you that HIV PrEP drugs (Apretude, cabotegravir, Descovy®, emtricitabine and tenofovir disoproxil fumarate, and Truvada®) may be covered under Medicare Part B for prevention of pre-exposure, effective late September 2024. However, if these prescription drugs are used to treat HIV, they will remain covered under Medicare Part D. This change is occurring in response to a proposed National Coverage Determination from the Centers for Medicare & Medicaid Services.
If your patients have their Medicare Part B benefit covered with a different health plan, they may need to inform their pharmacy to use that plan for coverage when these prescription drugs are being administered for pre-exposure prevention.
You can submit a request for Humana to make an exception by calling Humana Clinical Pharmacy Review at 800-555-CLIN (2546) (TTY:711), Monday – Friday, 8 a.m. – 6 p.m., Eastern time. For prescription drug coverage requests in Puerto Rico, please call 866-773-5959.
Information about the launch of generic Myrbetriq
Effective on the date of launch, April 27, 2024, generic Myrbetriq (mirabegron) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Myrbetriq will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
An important update regarding prescription drug coverage for tropicamide eye drops
To assist you in the care of your patients, we are notifying you that tropicamide eye drops will be removed from Humana’s formulary on July 15, 2024. Humana has determined that tropicamide eye drops are no longer eligible for Medicare Part D prescription drug coverage.
Sufficient clinical alternatives may not be available on Humana’s formulary, but we encourage you to use Humana’s Drug List formulary search tool on the
You also can submit a request for Humana to make an exception by calling Humana Clinical Pharmacy Review at 800-555-CLIN (2546) (TTY:711), Monday – Friday, 8 a.m. – 6 p.m., Eastern time. For drug coverage requests in Puerto Rico, please call 866-773-5959.
We have sent a letter to your Humana-covered patients who have had a claim for tropicamide eye drops to inform them of this midyear formulary change and encourage them to work with their healthcare provider on alternative options.
Information about the launch of generic Farxiga
Effective on the date of launch, Jan. 6, 2024, generic Farxiga (dapagliflozin) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Farxiga will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Xigduo XR
Effective on the date of launch, Jan. 6, 2024, generic Xigduo XR (dapagliflozin-metformin) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Xigduo XR will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Risperdal Consta
Effective on the date of launch, Dec. 16, 2023, generic Risperdal Consta (risperidone extended release) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Risperdal Consta will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Forteo
Effective on the date of launch, Nov. 25, 2023, generic Forteo (teriparatide) is not covered on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Forteo will continue to be covered with prior authorization and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Breo Ellipta
Effective on the date of launch, Jan. 1, 2024, generic Breo Ellipta (fluticasone furoate/vilanterol) is not covered on Humana’s commercial formularies, Medicare Advantage prescription drug plans and Medicare Part D plans. Brand-name Breo Ellipta will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Spiriva with HandiHaler
Effective on the date of launch, Jan. 1, 2024, generic Spiriva with HandiHaler (tiotropium bromide) is not covered or may require step therapy through the brand on Humana’s commercial formularies, Medicare Advantage prescription drug plans and Medicare Part D plans. Brand-name Spiriva with HandiHaler will continue to be covered and can be filled for your patients.
Prescribers with questions regarding this change can call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of generic Vascepa
Effective Jan. 1, 2023, generic Vascepa (icosapent) is not covered or may require step therapy on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Vascepa will continue to be covered and can be filled for patients.
Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Formulary changes for Revlimid
Lenalidomide, the generic version of Revlimid®, is covered by Humana with a prior authorization and will remain covered in 2023. Effective Jan. 1, 2023, Humana Medicare plans will no longer cover Revlimid. If the generic version is not available at your patient’s pharmacy, please include this information in your coverage exception request. We have notified your patients who had a claim for Revlimid in 2022 about this formulary change.
Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Updates could mean new requirements for Humana members
Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.
These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.
Information about the launch of generic Durezol
Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Information about the launch of authorized generic insulin aspart and insulin aspart mix
Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.
Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.
Med-Edit update notification
As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.